113 related articles for article (PubMed ID: 20618494)
1. FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study.
Bozdogan N; Bozdogan O; Pak I; Atasoy P
Int J Dermatol; 2010 Jul; 49(7):761-7. PubMed ID: 20618494
[TBL] [Abstract][Full Text] [Related]
2. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
3. [The relationship between Fas/FasL and proliferating cell nuclear antigen expression and malignant degree in human melanoma].
Wang YC; Tan Y
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):965-8. PubMed ID: 18756968
[TBL] [Abstract][Full Text] [Related]
4. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C
Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221
[TBL] [Abstract][Full Text] [Related]
5. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
7. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
8. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack.
Ohno S; Inagawa H; Dhar DK; Fujii T; Ueda S; Tachibana M; Ohno Y; Suzuki N; Inoue M; Soma G; Nagasue N
Anticancer Res; 2005; 25(1B):463-70. PubMed ID: 15816613
[TBL] [Abstract][Full Text] [Related]
9. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
10. Expression of Fas/FasL in patients with oral lichen planus.
Hadzi-Mihailovic M; Raybaud H; Monteil R; Jankovic L
J BUON; 2009; 14(3):487-93. PubMed ID: 19810143
[TBL] [Abstract][Full Text] [Related]
11. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
Younes M; Schwartz MR; Ertan A; Finnie D; Younes A
Cancer; 2000 Feb; 88(3):524-8. PubMed ID: 10649242
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.
Piras F; Colombari R; Minerba L; Murtas D; Floris C; Maxia C; Corbu A; Perra MT; Sirigu P
Cancer; 2005 Sep; 104(6):1246-54. PubMed ID: 16078259
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
16. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure.
Mita A; Hashikura Y; Tagawa Y; Nakayama J; Kawakubo M; Miyagawa S
Am J Gastroenterol; 2005 Nov; 100(11):2551-9. PubMed ID: 16279913
[TBL] [Abstract][Full Text] [Related]
17. The involvement of Fas/FasL interaction in porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus co-inoculation-associated lymphocyte apoptosis in vitro.
Chang HW; Jeng CR; Lin CM; Liu JJ; Chang CC; Tsai YC; Chia MY; Pang VF
Vet Microbiol; 2007 May; 122(1-2):72-82. PubMed ID: 17321702
[TBL] [Abstract][Full Text] [Related]
18. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.
Hallermalm K; De Geer A; Kiessling R; Levitsky V; Levitskaya J
Cancer Res; 2004 Sep; 64(18):6775-82. PubMed ID: 15374996
[TBL] [Abstract][Full Text] [Related]
19. [Fas receptor and Fas-ligand expression by cells of primary melanoma, effect on lymphoid infiltration through tumor bed and long-term results of therapy].
Kudriavtsev DV; Mardynskiĭ IuS; Dvinskikh NIu; Kudriavtseva GT
Vopr Onkol; 2008; 54(5):582-7. PubMed ID: 19069470
[TBL] [Abstract][Full Text] [Related]
20. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
